DewCell
Seongnam
About DewCell
DewCell develops artificial platelets through stem cell differentiation technology. The company possesses proprietary expertise in directing stem cells to differentiate into megakaryocytes, which produce platelets and are scaled for mass production in bioreactors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $6.6M
- Funding stage: Early Stage Venture
- Last round: Series B (Apr 2024)
- Website: dewcell.com
- Phone: +82-31-8023-9830
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/dewcell-149335 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.